Tak­ing an­oth­er shot at mR­NA glo­ry, Cure­Vac inks on­col­o­gy pact while keep­ing up with Covid work

Cure­Vac may have lost out on the ini­tial mR­NA race to bring a Covid-19 vac­cine to the mar­ket, but it’s still ea­ger to prove that it has what it takes to be a se­ri­ous play­er in the field.

As it up­dates in­vestors on its sec­ond-gen­er­a­tion vac­cine can­di­dates for in­fec­tious dis­eases in Q1 re­sults, the Ger­man biotech says it’s beef­ing up its on­col­o­gy pipeline.

To that end, it has struck a new col­lab­o­ra­tion with Bel­gium’s my­NEO, which boasts of a neoanti­gen dis­cov­ery and se­lec­tion plat­form, to iden­ti­fy new tar­gets for mR­NA im­munother­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER